# Quick Circulating AAT Testing Device Development

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Chief Innovation Officer
**Purpose**: Define strategy for developing rapid point-of-care AAT testing deviceâ€”enabling immediate diagnosis in primary care offices, urgent care, ERs, and home testing

---

## ðŸ“‹ Table of Contents

1. [Innovation Overview](#innovation-overview)
2. [The Problem: Current Testing Limitations](#the-problem-current-testing-limitations)
3. [The Solution: Rapid AAT Testing Device](#the-solution-rapid-aat-testing-device)
4. [Device Specifications](#device-specifications)
5. [Technology Options](#technology-options)
6. [Development Pathway](#development-pathway)
7. [Regulatory Strategy](#regulatory-strategy)
8. [Market & Distribution](#market--distribution)
9. [Business Model & Revenue](#business-model--revenue)
10. [Implementation Timeline](#implementation-timeline)

---

## Innovation Overview

### Vision: "The AAT Glucometer"

**Imagine**: A handheld device that measures circulating AAT levels in 5 minutes (like glucose monitoring for diabetes)

**Device Goals**:

- âœ… **Point-of-Care**: Use in doctor's office (no lab send-outâ€”results during appointment)
- âœ… **Rapid**: Results in 5-15 minutes (vs. 3-7 days for traditional lab test)
- âœ… **Easy**: Finger prick or saliva sample (no venipuncture, minimal training required)
- âœ… **Accurate**: FDA-cleared (comparable accuracy to gold-standard nephelometry)
- âœ… **Affordable**: $50-$100 per test (vs. $200+ for lab testâ€”insurance reimbursable)
- âœ… **Accessible**: Available in all primary care offices, urgent care, ERs, eventually home testing

**Impact**: Reduce diagnostic delay from 7-8 years to days/weeks (test symptomatic patients immediately)

---

### Strategic Importance

**Why This Device is Game-Changer**:

1. **Eliminates Testing Barrier**: Currently, doctors must order lab test (patient goes to lab, results take days, follow-up appointment needed). With rapid test, doctor gets result during visit â†’ immediate referral to specialist if abnormal
2. **Enables Screening**: Test all COPD patients at diagnosis (current recommendation, rarely followedâ€”too cumbersome). Rapid test makes screening feasible
3. **Home Monitoring**: Eventually, patients with AATD could self-test (monitor AAT levels during augmentation therapyâ€”like diabetics check glucose)
4. **Revenue Stream**: Foundation licenses technology to medical device company (royalties fund Foundation programsâ€”sustainable income)
5. **Mark's Legacy**: Uses Mark's patent insights (AAT protein research â†’ testing innovation)

---

## The Problem: Current Testing Limitations

### Current AAT Testing Process (Slow & Cumbersome)

**Step 1: Doctor Orders Test**:

- Patient presents with symptoms (shortness of breath, young-onset COPD)
- Doctor suspects AATD (or follows guidelines to screen all COPD patients)
- Orders serum AAT level test (blood draw)

**Step 2: Lab Processing**:

- Patient goes to lab (Quest, LabCorpâ€”separate appointment, travel)
- Phlebotomist draws blood (venipunctureâ€”some patients anxious about needles)
- Sample sent to lab (processed via nephelometry or immunoassay)
- Results take 3-7 days (sometimes longer)

**Step 3: Follow-Up**:

- Doctor reviews results (days later)
- If abnormal (low AAT), orders confirmatory genetic test (another lab visit, another wait)
- Patient returns for follow-up appointment (discuss results, next steps)

**Total Time**: 2-4 weeks (from suspicion to diagnosis)

---

### Why This Process Fails

**1. Patient Drop-Off** (30-40% Never Complete Testing):

- Doctor orders test â†’ patient forgets, procrastinates, or can't get to lab
- Results come back â†’ patient doesn't schedule follow-up (assumes no news = good news)
- Abnormal result â†’ patient overwhelmed, doesn't follow through with genetic testing

**2. Doctor Inertia**:

- Ordering lab test is extra work (EMR documentation, lab requisition, scheduling follow-up)
- No immediate feedback (doctor forgets, patient lost to follow-up)
- Low awareness of AATD (many doctors don't order test because "I've never seen a case")

**3. Access Barriers**:

- Rural patients (nearest lab 50+ miles awayâ€”not feasible)
- Uninsured patients (lab test $200-$400 out-of-pocketâ€”can't afford)
- Urgent care/ER settings (can't order send-out testsâ€”patient discharged before results)

**Result**: 7-8 year average diagnostic delay (300,000 Americans undiagnosed)

---

## The Solution: Rapid AAT Testing Device

### How It Works (Patient Perspective)

**Scenario: Primary Care Office**:

1. **Patient visits doctor** (shortness of breath, cough, wheezing)
2. **Doctor suspects AATD** (young patient, non-smoker, family historyâ€”or routine COPD screening)
3. **Doctor performs rapid test** (finger prick, drop of blood on test strip, insert in device)
4. **Device analyzes sample** (immunoassay, biosensorâ€”measures AAT concentration)
5. **Results in 5-15 minutes** (device displays AAT level: Normal >90 mg/dL, Abnormal <90 mg/dL)
6. **Immediate Action**: If abnormal â†’ doctor orders genetic testing, refers to pulmonologist (same visitâ€”no lost follow-up)

**Patient Impact**: "I came in with a cough, walked out knowing I might have AATD, already scheduled with specialist."

---

### Comparison to Current Process

| Aspect                 | **Traditional Lab Test**   | **Rapid AAT Device**              |
| ---------------------- | -------------------------- | --------------------------------- |
| **Sample**             | Venous blood draw          | Finger prick or saliva            |
| **Location**           | Separate lab visit         | Doctor's office (point-of-care)   |
| **Time to Results**    | 3-7 days                   | 5-15 minutes                      |
| **Follow-Up Needed**   | Yes (separate appointment) | No (results same visit)           |
| **Patient Compliance** | 60-70% complete            | 95%+ complete (done during visit) |
| **Cost**               | $200-$400 (lab fees)       | $50-$100 (device + test strip)    |
| **Accessibility**      | Requires lab access        | Available anywhere device is      |

---

## Device Specifications

### Target Product Profile

**Form Factor**:

- Handheld device (size of glucometerâ€”fits in doctor's coat pocket)
- Battery-powered or rechargeable (no wall outlet required)
- Touchscreen display (show results, store patient history)
- Bluetooth connectivity (sync with EMR, upload data to cloud)

**Sample Type** (3 Optionsâ€”Choose 1 or Support Multiple):

1. **Finger Prick Blood** (most accurate, similar to glucose testing)
2. **Saliva** (least invasive, but lower accuracyâ€”may need larger sample volume)
3. **Capillary Blood from Earlobe** (alternative to fingerâ€”some prefer)

**Test Strip**:

- Single-use disposable strip (insert blood sample, device reads)
- Shelf-stable (6-12 months at room temperatureâ€”no refrigeration)
- Cost: $10-$20 per strip (targetâ€”insurance reimbursable)

**Performance**:

- **Accuracy**: 95%+ correlation with nephelometry (gold standardâ€”FDA requirement)
- **Range**: 20-200 mg/dL (cover full range from severe deficiency to normal)
- **Precision**: CV <10% (coefficient of variationâ€”reproducibility)
- **Time to Result**: 5-15 minutes (target <10 min)

**Connectivity**:

- Bluetooth to smartphone app (patient/doctor can track results over time)
- Wi-Fi or cellular (upload to cloud for research, monitoring)
- EMR integration (results auto-populate patient chartâ€”reduce documentation burden)

---

### User Interface

**Device Display**:

- **Results Screen**: Shows AAT level (e.g., "55 mg/dL"), interpretation ("LOWâ€”Refer to specialist")
- **History**: Store last 100 tests (patient can track over time if monitoring augmentation therapy)
- **Error Messages**: "Sample insufficient," "Test strip expired," "Device errorâ€”contact support"

**Smartphone App** (Optional Enhancementâ€”Year 2):

- Track AAT levels over time (graph trendsâ€”useful for patients on therapy)
- Reminders (test every 6 months if on augmentation therapy)
- Share with doctor (export PDF report)

---

## Technology Options

### Option 1: Lateral Flow Immunoassay (Simplest)

**How It Works**:

- Similar to pregnancy test or COVID rapid test
- Blood sample applied to test strip (capillary action pulls sample along strip)
- AAT binds to antibody (creates visible lineâ€”intensity correlates with concentration)
- Device reads line intensity (optical sensor), calculates AAT level

**Pros**:

- âœ… Simple, mature technology (many FDA-cleared lateral flow tests exist)
- âœ… Low cost per test ($10-$20â€”similar to glucose strips)
- âœ… No electricity required (can be fully manualâ€”visual read)

**Cons**:

- âŒ Lower precision (CV 10-15%â€”acceptable for screening, but less accurate than lab)
- âŒ Limited dynamic range (hard to measure very low or very high AAT accurately)

**Best For**: Screening in resource-limited settings (developing countries, rural clinics)

---

### Option 2: Electrochemical Biosensor (Preferredâ€”Like Glucose Meters)

**How It Works**:

- Blood sample applied to test strip (contains electrodes coated with AAT antibody)
- AAT binds to antibody (changes electrical currentâ€”proportional to AAT concentration)
- Device measures current, calculates AAT level

**Pros**:

- âœ… High accuracy (CV <5%â€”comparable to lab nephelometry)
- âœ… Fast (results in 5 minutes)
- âœ… Proven technology (glucose meters use same principleâ€”regulatory path clear)
- âœ… Quantitative (precise number, not just "high/low")

**Cons**:

- âŒ Moderate cost ($30-$50 per testâ€”higher than lateral flow, but still affordable)
- âŒ Requires device (can't do manual readâ€”need handheld reader)

**Best For**: Point-of-care in US (doctor's offices, urgent care, ERs)

---

### Option 3: Microfluidic Lab-on-Chip (Most Advanced)

**How It Works**:

- Blood sample loaded into cartridge (microfluidic channels separate plasma, mix with reagents)
- AAT reacts with detection antibody (fluorescence or colorimetric signal)
- Optical sensor reads signal, calculates AAT level

**Pros**:

- âœ… Highest accuracy (matches gold-standard nephelometryâ€”could replace lab testing entirely)
- âœ… Multi-analyte potential (could test AAT + other biomarkers in one cartridge)
- âœ… Fully automated (minimal user skill required)

**Cons**:

- âŒ High cost ($100-$200 per testâ€”expensive, insurance reimbursement uncertain)
- âŒ Complex device (expensive readerâ€”$5K-$10K, limits distribution)
- âŒ Longer development time (bleeding-edge tech, regulatory risk)

**Best For**: Hospital labs, AATD centers of excellence (not primary care)

---

### Recommendation: Start with Option 2 (Electrochemical Biosensor)

**Rationale**:

- Proven technology (glucose meters have cleared regulatory path)
- High accuracy (FDA will accept, doctors will trust)
- Affordable ($30-$50 per testâ€”insurance will reimburse)
- Fast development (2-3 years to market vs. 5+ for lab-on-chip)

**Pivot Strategy**: If successful, develop Option 1 (lateral flow) for international markets, Option 3 (lab-on-chip) for premium/hospital use

---

## Development Pathway

### Phase 1: Proof of Concept (Year 1â€”Months 1-12)

**Objective**: Demonstrate feasibility (can we measure AAT accurately with biosensor?)

**Activities**:

- **Literature Review**: Existing AAT immunoassays, biosensor technology, patents (avoid infringement)
- **Partner Identification**: Academic labs (biomedical engineeringâ€”university partnership), diagnostic companies (interested in licensing technology)
- **Prototype Development**: Build benchtop prototype (test various biosensor designs, antibodies, sample prep methods)
- **Validation**: Test with human samples (donated by AATD patientsâ€”range of AAT levels), compare to nephelometry (gold standard)

**Deliverable**: Proof-of-concept report ("We can measure AAT with biosensor, accuracy 95%+ vs. lab")

**Budget**: $250K (university partnership, materials, validation studies)

---

### Phase 2: Device Development (Year 2-3â€”Months 13-36)

**Objective**: Build functional prototype device (handheld, user-friendly, manufacturable)

**Activities**:

- **Industrial Design**: Handheld form factor (ergonomics, user interface, aesthetics)
- **Engineering**: Electronics (biosensor reader, display, battery, connectivity), software (results calculation, data storage, EMR integration)
- **Test Strip Development**: Manufacture test strips at scale (antibody coating, electrode printing, quality control)
- **Alpha Testing**: Test with 100 patients (clinic settingâ€”doctors use device, compare to lab)
- **Beta Testing**: Test with 500 patients (10 clinicsâ€”real-world use, refine based on feedback)

**Deliverable**: Functional prototype device + test strips (ready for clinical validation)

**Budget**: $2M (engineering team, materials, clinical testing)

---

### Phase 3: Clinical Validation (Year 3-4â€”Months 37-48)

**Objective**: Prove device is accurate, reliable, safe (FDA submission-ready)

**Activities**:

- **Clinical Study**: Enroll 1,000 patients (20 sitesâ€”mix of primary care, pulmonology, AATD centers)
- **Comparator**: Device vs. nephelometry (gold standardâ€”every patient gets both tests)
- **Endpoints**: Sensitivity (% of low AAT correctly identified), specificity (% of normal AAT correctly identified), correlation (device vs. lab values)
- **FDA Pre-Submission**: Meet with FDA (discuss study design, endpoints, regulatory pathwayâ€”CLIA waiver potential)

**Deliverable**: Clinical validation report (demonstrate 95%+ accuracy, ready for FDA submission)

**Budget**: $3M (clinical study, FDA consulting, CRO management)

---

### Phase 4: FDA Clearance (Year 4-5â€”Months 49-60)

**Objective**: Obtain FDA clearance (510(k) pathwayâ€”most likely)

**Activities**:

- **510(k) Submission**: Submit to FDA (device description, clinical data, manufacturing quality, labeling)
- **FDA Review**: 3-6 months (FDA asks questions, requests additional dataâ€”common)
- **Clearance**: FDA approves device for sale (Class II medical deviceâ€”moderate risk)
- **CLIA Waiver** (Optional): Apply for waiver (allows use by non-lab personnelâ€”critical for point-of-care)

**Deliverable**: FDA clearance letter (device can be marketed in US)

**Budget**: $500K (FDA submission, regulatory consulting, quality systems)

---

### Phase 5: Commercialization (Year 5+â€”Months 61+)

**Objective**: Manufacture, distribute, sell device (or license to partner)

**Activities**:

- **Manufacturing Scale-Up**: Contract manufacturer (produce 10K-100K devices/year)
- **Sales & Distribution**: Direct sales to clinics, hospitals, labs OR partner with diagnostic company (e.g., Abbott, Rocheâ€”they handle sales)
- **Reimbursement**: Obtain CPT code (insurance reimbursementâ€”critical for adoption), negotiate pricing with payers
- **Post-Market Surveillance**: Track device performance (adverse events, accuracy in real-world useâ€”FDA requirement)

**Deliverable**: Device on market (sold to clinics, insurance reimbursed, patients tested)

**Budget**: $5M+ (manufacturing, sales, marketingâ€”or funded by licensing partner)

---

## Regulatory Strategy

### FDA Pathway: 510(k) Clearance (Most Likely)

**Why 510(k)**:

- Device is "substantially equivalent" to existing cleared device (e.g., glucose meter, other immunoassay devices)
- Class II device (moderate riskâ€”not life-sustaining, but medical decision tool)
- Faster than PMA (510(k) takes 3-6 months, PMA takes 1-3 years)

**Predicate Devices** (Examples of Similar Cleared Devices):

- Abbott i-STAT (point-of-care blood analyzerâ€”cleared for various immunoassays)
- Siemens DCA Vantage (point-of-care HbA1c analyzerâ€”similar biosensor technology)
- Alere Cholestech LDX (lipid panel analyzerâ€”finger prick sample, rapid results)

**FDA Requirements**:

- Clinical validation (1,000+ patients, demonstrate accuracy vs. lab)
- Analytical validation (precision, linearity, interference studies)
- Quality systems (ISO 13485â€”manufacturing quality management)
- Labeling (instructions for use, warnings, limitations)

---

### CLIA Waiver (Critical for Point-of-Care Use)

**What is CLIA Waiver**:

- Allows device to be used by non-lab personnel (doctors, nurses, medical assistants)
- Without waiver, only certified lab technicians can perform test (limits point-of-care use)

**Requirements for Waiver**:

- Simple to use (minimal training required)
- Low error risk (device has built-in quality control)
- Accurate (comparable to lab test)

**Strategy**: Apply for CLIA waiver simultaneously with 510(k) (or shortly after clearance)

---

### International Regulatory (Future)

**CE Mark** (European Union):

- Required to sell in EU (easier than FDAâ€”self-certification or notified body review)
- Timeline: 6-12 months after FDA clearance

**Other Markets** (Canada, Australia, Asia):

- Often accept FDA clearance (or require minimal additional testing)
- Partner with local distributor (handle regulatory, sales)

---

## Market & Distribution

### Target Markets (Prioritized)

**1. Primary Care Offices** (Highest Impact):

- 200,000+ primary care physicians in US (first point of contact for most AATD patients)
- Test symptomatic patients immediately (cough, shortness of breath, family history)
- **Market Size**: 50,000 offices buy device (assume 25% adoption) Ã— 10 tests/year = 500K tests/year

**2. Pulmonology Practices**:

- 15,000 pulmonologists in US (diagnose/treat COPD, AATD)
- Screen all new COPD patients (current guideline, rarely followedâ€”device makes it easy)
- **Market Size**: 10,000 pulmonologists Ã— 50 tests/year = 500K tests/year

**3. Urgent Care & ERs**:

- Patients present with acute respiratory symptoms (exacerbation, pneumonia)
- Test if suspect AATD (young, severe symptoms, non-smoker)
- **Market Size**: 10,000 urgent care/ERs Ã— 20 tests/year = 200K tests/year

**4. AATD Centers of Excellence**:

- 50+ specialized AATD clinics (Cleveland Clinic, National Jewish, Mayo, etc.)
- Monitor patients on augmentation therapy (check AAT levels during treatmentâ€”quarterly or monthly)
- **Market Size**: 10,000 AATD patients on therapy Ã— 4 tests/year = 40K tests/year

**5. Home Testing** (Year 5+ Vision):

- Patients self-test (like diabetics test glucoseâ€”daily or weekly)
- Monitor augmentation therapy effectiveness (are AAT levels staying normal?)
- **Market Size**: 10,000 patients Ã— 52 tests/year = 520K tests/year (long-term potential)

**Total Addressable Market**: 1.76M tests/year (US onlyâ€”grow internationally Year 5+)

---

### Distribution Strategy

**Option 1: Direct Sales** (Foundation Sells Device):

- **Pros**: Higher margin (keep all revenue), control brand, direct relationship with customers
- **Cons**: Requires sales team (expensive), slow market penetration, regulatory burden (Foundation becomes device manufacturer)

**Option 2: Licensing to Diagnostic Company** (Recommended):

- **Partner Options**: Abbott, Roche, Siemens, Beckman Coulter (established device companies with sales infrastructure)
- **Structure**: Foundation licenses technology (royalty on each test soldâ€”e.g., $5-$10 per test)
- **Pros**: Partner handles manufacturing, sales, regulatory, reimbursement (Foundation focuses on mission, not device business)
- **Cons**: Lower revenue per test (but higher volume, less risk)

**Recommendation**: Develop through Phase 3 (clinical validation), then license to partner (Year 4-5)

**Rationale**: Foundation's mission is patient impact, not device sales. Partner has expertise, resources, distribution network â†’ faster adoption, wider impact

---

## Business Model & Revenue

### Revenue Projections (If Foundation Licenses to Partner)

**Assumptions**:

- Market penetration: 10% Year 1, 25% Year 3, 50% Year 5 (of 1.76M test market)
- Royalty: $5 per test (conservativeâ€”glucose strips pay $2-$5, AAT test could command higher)

**Year 1** (Post-Clearance):

- 176,000 tests Ã— $5 royalty = **$880K revenue**

**Year 3**:

- 440,000 tests Ã— $5 = **$2.2M revenue**

**Year 5**:

- 880,000 tests Ã— $5 = **$4.4M revenue**

**10-Year Projection**: $30M+ cumulative revenue (sustains Foundation operations indefinitely)

---

### Cost to Foundation (Development Investment)

**Phase 1 (Proof of Concept)**: $250K
**Phase 2 (Device Development)**: $2M
**Phase 3 (Clinical Validation)**: $3M
**Phase 4 (FDA Clearance)**: $500K

**Total Development Cost**: $5.75M (Years 1-5)

**ROI**: Break-even in Year 7 (after $5.75M recouped via royalties), then $2M-$4M/year profit (funds Foundation programs in perpetuity)

---

### Funding Strategy

**Phase 1**: Foundation funds (use initial donationsâ€”$250K)

**Phase 2-3**: Raise dedicated funding:

- NIH SBIR/STTR grant ($1.5Mâ€”Small Business Innovation Research for medical devices)
- Corporate partnership (diagnostic company co-funds development in exchange for licensing option)
- Major donor ($2M giftâ€”"Your donation will develop breakthrough diagnostic device")

**Phase 4-5**: Licensing partner funds (once partner signed, they fund FDA submission, commercialization)

---

## Implementation Timeline

### 5-Year Roadmap

**Year 1: Proof of Concept**

- Q1-Q2: Literature review, partner identification, prototype design
- Q3-Q4: Benchtop testing, validation with patient samples (n=100)
- **Milestone**: Proof-of-concept report (95%+ accuracy demonstrated)

**Year 2: Device Development**

- Q1-Q2: Industrial design, engineering (handheld device, test strips)
- Q3-Q4: Alpha testing (100 patients, 5 clinics)
- **Milestone**: Functional prototype ready for beta testing

**Year 3: Beta Testing & Clinical Study Design**

- Q1-Q2: Beta testing (500 patients, 10 clinics)
- Q3-Q4: Clinical study initiation (enroll 1,000 patients)
- **Milestone**: Clinical study enrollment complete

**Year 4: Clinical Validation & FDA Submission**

- Q1-Q2: Clinical study completion, data analysis
- Q3-Q4: 510(k) submission to FDA
- **Milestone**: FDA submission filed

**Year 5: FDA Clearance & Licensing**

- Q1-Q2: FDA review, response to FDA questions
- Q3: FDA clearance obtained
- Q4: License to partner, manufacturing scale-up begins
- **Milestone**: Device on market

---

## Success Metrics

### Development Milestones

**Technical**:

- âœ… Proof of concept (95%+ accuracy vs. nephelometryâ€”Year 1)
- âœ… Functional prototype (handheld device, test stripsâ€”Year 2)
- âœ… Clinical validation (1,000 patients, FDA-ready dataâ€”Year 4)
- âœ… FDA clearance (510(k) approvedâ€”Year 5)

**Business**:

- âœ… Licensing deal signed (partner commits to commercializeâ€”Year 4-5)
- âœ… Market launch (device available for purchaseâ€”Year 5)
- âœ… Reimbursement (CPT code, insurance coverageâ€”Year 5-6)

---

### Impact Metrics (Post-Launch)

**Diagnostic Delay Reduction**:

- Baseline: 7-8 years average diagnostic delay
- Target: <1 year (with rapid testing, catch most patients within months of symptom onset)

**Testing Volume**:

- Year 1: 176,000 tests (10% market penetration)
- Year 5: 880,000 tests (50% market penetration)
- Year 10: 1.76M tests/year (full marketâ€”every symptomatic patient tested)

**New Diagnoses**:

- Current: ~2,000 new diagnoses/year (US)
- With Device: 10,000+ new diagnoses/year (5x increaseâ€”catch previously missed patients)

**Revenue to Foundation**:

- Year 1: $880K (royalties fund patient programs)
- Year 5: $4.4M/year (sustains Foundation indefinitely)

---

## Summary

**Rapid AAT Testing Device = Game-Changer for AATD**:

- âœ… **Reduces Diagnostic Delay**: From 7-8 years to days/weeks (test during office visit, immediate results)
- âœ… **Increases Diagnosis Rate**: 5x more patients diagnosed (easier testing = more doctors screen)
- âœ… **Enables Monitoring**: Patients on therapy self-test (optimize treatment, early detection of therapy failure)
- âœ… **Sustainable Revenue**: $2M-$4M/year royalties (fund Foundation programs in perpetuity)
- âœ… **Mark's Legacy**: Innovation rooted in Mark's AAT protein research (patent commercialization)

**5-Year Development â†’ Market Launch â†’ Transform AATD Diagnosis Forever**

**"Every patient deserves a fast, accurate diagnosis. This device makes it possible."**

---

**Questions or Want to Support Device Development?**

**Mark Egly Foundation Innovation Lab**
ðŸ“§ Email: innovation@markeglyfoundation.org
ðŸ’¡ Partner Inquiries: partnerships@markeglyfoundation.org

---

**Approved by**: Board of Directors
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"Innovation saves lives. Let's build the future of AATD diagnosis."_

**â€” Mark Egly Foundation**
